What are the contraindications to Moujaro (tirzepatide) in patients with type 2 diabetes, particularly those with a history of medullary thyroid carcinoma, pancreatitis, or impaired renal function?

Contraindications to Moujaro (Tirzepatide)

Absolute Contraindications

Moujaro is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). 1, 2, 3

• This contraindication is based on rodent studies showing thyroid C-cell tumors, though human relevance has not been definitively established 1, 2
• The contraindication applies even if the patient has not undergone genetic testing for MEN 2 4
• This is a class effect for all GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists 4, 3

History of Pancreatitis

Do not initiate Moujaro in patients at high risk for pancreatitis, and permanently discontinue if pancreatitis is confirmed. 1, 5

• If acute pancreatitis is definitively diagnosed while on tirzepatide, there is an absolute contraindication to restart any GLP-1 or dual GIP/GLP-1 medication 5
• Acute pancreatitis has been reported with GLP-1 receptor agonists, though causality has not been definitively established 1, 6
• If pancreatitis was only suspected but never confirmed, use extreme caution and consider alternative agents 5

Pregnancy and Breastfeeding

Moujaro is contraindicated in pregnancy and breastfeeding. 7, 2

• Women of reproductive potential must use reliable contraception 7
• For patients using oral hormonal contraceptives, consider switching to non-oral methods or adding barrier methods for 4 weeks after initiation and each dose escalation due to delayed gastric emptying affecting absorption 1, 2

Relative Contraindications and Precautions

Gastroparesis

Moujaro is not recommended in patients with clinically meaningful gastroparesis. 1, 2

• Tirzepatide delays gastric emptying and will worsen gastroparesis symptoms 1, 2
• Patients with prior gastric surgery, including bariatric procedures, require extreme caution 2

Gallbladder Disease

Avoid use in patients at high risk for gallbladder disease. 1

• Evaluate for gallbladder disease if cholelithiasis or cholecystitis is suspected 1
• There is an increased risk of gallstones and cholecystitis, particularly with rapid weight loss 7, 2

Diabetic Retinopathy

Close monitoring is required in patients at high risk for diabetic retinopathy. 1

• This particularly applies to older individuals and those with longer duration of type 2 diabetes (≥10 years) 1
• Monitor closely for progression of diabetic retinopathy 2

Renal Impairment Considerations

No dose adjustment is required for renal impairment, including end-stage renal disease. 1, 8, 9

• Tirzepatide exposure is similar across all levels of renal function 8
• Monitor renal function closely when initiating or escalating doses, especially in patients experiencing severe gastrointestinal side effects that could lead to dehydration 2, 9
• Tirzepatide has demonstrated positive effects on albuminuria without detrimental effects on eGFR 9, 10

Critical Dosing Considerations

Always start at the lowest dose (2.5 mg weekly) and titrate slowly to minimize gastrointestinal side effects. 1, 2

• Starting at high doses bypasses the body's adaptation period to delayed gastric emptying, dramatically increasing risk of severe nausea, vomiting, and dehydration 2
• Impact on drug absorption may occur during dose titration, particularly affecting medications with narrow therapeutic indices 1, 2

Hypoglycemia Risk

When combined with insulin or sulfonylureas, reduce doses of these medications to prevent hypoglycemia. 1, 2

• Tirzepatide itself has minimal intrinsic hypoglycemia risk due to glucose-dependent insulin secretion 1
• Increased hypoglycemia risk occurs only when combined with insulin secretagogues 1, 2